Superworth

BioCardia price to book ratio BCDA

Market value divided by the book value of the company's net assets, since 2011.

Today, Nov 2, 2026
5.1×
10-year median
18.2×
Against its 10-year history
7th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.1× to 189×
Peer median
1.5×

BioCardia's price to book ratio is 5.1× as of Nov 2, 2026.

That is below its ten-year median of 18.2×, lower than on 93% of days in the last ten years.

Over that time it ranged from 3.1× in Nov 2024 to 189× in May 2019.

The median for 7 healthcare stocks of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.1×4.6×14.7×
20255.1×3.3×15.9×
20244.1×3.1×4.1×
202315.9×15.0×89.1×
202227.3×5.4×27.3×
20217.3×6.6×46.5×
202031.4×9.8×41.0×
201914.7×14.2×189×
201838.2×14.5×97.5×
201719.5×18.0×49.4×
201639.0×3.5×39.0×
20154.0×3.0×6.7×
20146.2×4.2×7.2×
20134.7×3.1×8.3×
20123.0×3.0×5.4×
20113.6×2.9×5.7×

Against its peers

Companies in Healthcare nearest BioCardia's size, closest first, today.

CompanyPrice to book ratio
BCDABioCardia5.1×
NEPHNephros2.9×
ATNMActinium Pharmaceuticals1.5×
APTAlpha Pro Tech0.9×
SPROSpero Therapeutics1.4×
LFVNLifevantage2.2×
ICCCImmucell3.1×
KEQUKewaunee Scientific1.3×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on BioCardia

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.